Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 515

1.

Radium-223 mechanism of action: implications for use in treatment combinations.

Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G.

Nat Rev Urol. 2019 Nov 11. doi: 10.1038/s41585-019-0251-x. [Epub ahead of print] Review.

PMID:
31712765
2.

Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.

Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA.

Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312. eCollection 2019.

3.

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer.

Umbreen S, Banday MM, Jamroze A, Mansini AP, Ganaie AA, Ferrari MG, Maqbool R, Beigh FH, Murugan P, Morrissey C, Corey E, Konety BR, Saleem M.

Mol Cancer Ther. 2019 Nov;18(11):2111-2123. doi: 10.1158/1535-7163.MCT-19-0150. Epub 2019 Aug 29.

PMID:
31467179
4.

Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.

Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y.

Oncogene. 2019 Nov;38(45):7060-7072. doi: 10.1038/s41388-019-0947-7. Epub 2019 Aug 13.

PMID:
31409897
5.

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.

Sci Transl Med. 2019 Jul 31;11(503). pii: eaaw4993. doi: 10.1126/scitranslmed.aaw4993.

6.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130:4492-4505. doi: 10.1172/JCI128212.

7.

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.

J Clin Invest. 2019 Jul 16;130:4245-4260. doi: 10.1172/JCI127613.

8.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print]

PMID:
31227306
9.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
10.

Lineage relationship between prostate adenocarcinoma and small cell carcinoma.

Kanan AD, Corey E, Vêncio RZN, Ishwar A, Liu AY.

BMC Cancer. 2019 May 30;19(1):518. doi: 10.1186/s12885-019-5680-7.

11.

Publisher Correction: A ribonucleoprotein octamer for targeted siRNA delivery.

Tai W, Li J, Corey E, Gao X.

Nat Biomed Eng. 2018 Aug;2(8):622. doi: 10.1038/s41551-018-0272-4.

PMID:
31015633
12.

A ribonucleoprotein octamer for targeted siRNA delivery.

Tai W, Li J, Corey E, Gao X.

Nat Biomed Eng. 2018 May;2(5):326-337. doi: 10.1038/s41551-018-0214-1. Epub 2018 Apr 2. Erratum in: Nat Biomed Eng. 2018 Aug;2(8):622.

PMID:
30936447
13.

A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.

Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X, Ungerleider N, Baddoo M, Zhang W, Corey E, Vessella RL, Dong X, Zhang K, Yu X, Flemington EK, Dong Y.

Oncogene. 2019 Jun;38(25):4977-4989. doi: 10.1038/s41388-019-0768-8. Epub 2019 Feb 28.

14.

Maternal age alters offspring lifespan, fitness, and lifespan extension under caloric restriction.

Bock MJ, Jarvis GC, Corey EL, Stone EE, Gribble KE.

Sci Rep. 2019 Feb 28;9(1):3138. doi: 10.1038/s41598-019-40011-z.

15.

Method for the Direct Enantioselective Synthesis of Chiral Primary α-Amino Ketones by Catalytic α-Amination.

Han Y, Corey EJ.

Org Lett. 2019 Jan 4;21(1):283-286. doi: 10.1021/acs.orglett.8b03733. Epub 2018 Dec 21.

PMID:
30576160
16.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

17.

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.

Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.

Sci Rep. 2018 Nov 22;8(1):17239. doi: 10.1038/s41598-018-35417-0.

18.

Enantioselective Conversion of Oligoprenol Derivatives to Macrocycles in the Germacrene, Cembrene, and 18-Membered Cyclic Sesterterpene Series.

Reddy DS, Corey EJ.

J Am Chem Soc. 2018 Dec 12;140(49):16909-16913. doi: 10.1021/jacs.8b10522. Epub 2018 Nov 28.

PMID:
30466258
19.

Follow-up ecological studies for cryptic species discoveries: Decrypting the leopard frogs of the eastern U.S.

Schlesinger MD, Feinberg JA, Nazdrowicz NH, Kleopfer JD, Beane JC, Bunnell JF, Burger J, Corey E, Gipe K, Jaycox JW, Kiviat E, Kubel J, Quinn DP, Raithel C, Scott PA, Wenner SM, White EL, Zarate B, Shaffer HB.

PLoS One. 2018 Nov 9;13(11):e0205805. doi: 10.1371/journal.pone.0205805. eCollection 2018.

20.

Congeneric variability in lifespan extension and onset of senescence suggest active regulation of aging in response to low temperature.

Gribble KE, Moran BM, Jones S, Corey EL, Mark Welch DB.

Exp Gerontol. 2018 Dec;114:99-106. doi: 10.1016/j.exger.2018.10.023. Epub 2018 Nov 3.

21.

Synthesis of Chiral Cyclic Alcohols from Chiral Epoxides by H or N Substitution with Frontside Displacement.

da Silva Gomes R, Reddy KM, Corey EJ.

Org Lett. 2018 Oct 5;20(19):6310-6313. doi: 10.1021/acs.orglett.8b02822. Epub 2018 Sep 26.

PMID:
30256646
22.

Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.

Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.

Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21.

23.

A ribonucleoprotein octamer for targeted siRNA delivery.

Tai W, Li J, Corey E, Gao X.

Nat Biomed Eng. 2018;2:326-337. Epub 2018 Jul 12.

24.

Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.

Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS.

Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4.

PMID:
30181386
25.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
26.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.

Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH.

Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31.

27.

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.

Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S.

Clin Cancer Res. 2018 Nov 1;24(21):5458-5470. doi: 10.1158/1078-0432.CCR-18-0549. Epub 2018 Jul 18.

28.

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.

Lam HM, Corey E.

Front Oncol. 2018 May 22;8:167. doi: 10.3389/fonc.2018.00167. eCollection 2018. No abstract available.

29.

Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Lam HM, Nguyen HM, Corey E.

Methods Mol Biol. 2018;1786:1-27. doi: 10.1007/978-1-4939-7845-8_1.

30.

A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.

Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K.

Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10.

31.

Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.

Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. doi: 10.1073/pnas.1802354115. Epub 2018 Apr 23.

32.

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.

33.

Highly Diastereoselective Cationic Cyclization Reactions Convert a Common Monocyclic Enone to Bicyclic Precursors for the Synthesis of Retigeranic Acids A and B.

Breitler S, Han Y, Corey EJ.

Org Lett. 2017 Dec 15;19(24):6686-6687. doi: 10.1021/acs.orglett.7b03412. Epub 2017 Dec 1.

PMID:
29192787
34.

Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.

Baena-Del Valle JA, Zheng Q, Hicks JL, Fedor H, Trock BJ, Morrissey C, Corey E, Cornish TC, Sfanos KS, De Marzo AM.

Am J Clin Pathol. 2017 Nov 2;148(5):398-415. doi: 10.1093/ajcp/aqx094.

35.

Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer.

Pan H, Jansson KH, Beshiri ML, Yin J, Fang L, Agarwal S, Nguyen H, Corey E, Zhang Y, Liu J, Fan H, Lin H, Kelly K.

Oncotarget. 2017 Aug 24;8(44):77181-77194. doi: 10.18632/oncotarget.20424. eCollection 2017 Sep 29.

36.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

37.

Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.

Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM.

ACS Chem Biol. 2017 Nov 17;12(11):2804-2814. doi: 10.1021/acschembio.6b01035. Epub 2017 Oct 11.

38.

Simple Enantioselective Syntheses of (2R,6R)-Hydroxynorketamine and Related Potential Rapid-Onset Antidepressants.

Han Y, Mahender Reddy K, Corey EJ.

Org Lett. 2017 Oct 6;19(19):5224-5227. doi: 10.1021/acs.orglett.7b02498. Epub 2017 Sep 11.

PMID:
28892391
39.

Delivering Emotions.

Corey E.

JAMA. 2017 Sep 5;318(9):797-798. doi: 10.1001/jama.2017.7129. No abstract available.

PMID:
28873165
40.

Useful Applications of Enantioselective (4 + 2)-Cycloaddition Reactions to the Synthesis of Chiral 1,2-Amino Alcohols, 1,2-Diamines, and β-Amino Acids.

Mahender Reddy K, Thirupathi B, Corey EJ.

Org Lett. 2017 Sep 15;19(18):4956-4959. doi: 10.1021/acs.orglett.7b02437. Epub 2017 Aug 31.

PMID:
28858513
41.

Method for Highly Enantioselective Ligation of Two Chiral C(sp3) Stereocenters.

Bhimireddy E, Corey EJ.

J Am Chem Soc. 2017 Aug 16;139(32):11044-11047. doi: 10.1021/jacs.7b07366. Epub 2017 Aug 7.

PMID:
28759226
42.

A New, Short, and Stereocontrolled Synthesis of C2-Symmetric 1,2-Diamines.

Vemula R, Wilde NC, Goreti R, Corey EJ.

Org Lett. 2017 Jul 21;19(14):3883-3886. doi: 10.1021/acs.orglett.7b01768. Epub 2017 Jul 11.

PMID:
28696724
43.

Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.

Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, Vasioukhin V, Nelson P, Corey E, Üren A, Morrissey C.

Anticancer Res. 2017 Jul;37(7):3385-3396.

PMID:
28668826
44.

A novel iterative mixed model to remap three complex orthopedic traits in dogs.

Huang M, Hayward JJ, Corey E, Garrison SJ, Wagner GR, Krotscheck U, Hayashi K, Schweitzer PA, Lust G, Boyko AR, Todhunter RJ.

PLoS One. 2017 Jun 14;12(6):e0176932. doi: 10.1371/journal.pone.0176932. eCollection 2017.

45.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

46.

Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.

Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA.

Mol Cancer Res. 2017 May;15(5):521-531. doi: 10.1158/1541-7786.MCR-16-0315-T.

47.

Physiological effects of environmentally relevant, multi-day thermal stress on wild juvenile Atlantic salmon (Salmo salar).

Corey E, Linnansaari T, Cunjak RA, Currie S.

Conserv Physiol. 2017 Feb 27;5(1):cox014. doi: 10.1093/conphys/cox014. eCollection 2017.

48.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A.

Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

49.

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.

Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.

50.

Candidate pheromone receptors of codling moth Cydia pomonella respond to pheromones and kairomones.

Cattaneo AM, Gonzalez F, Bengtsson JM, Corey EA, Jacquin-Joly E, Montagné N, Salvagnin U, Walker WB, Witzgall P, Anfora G, Bobkov YV.

Sci Rep. 2017 Jan 24;7:41105. doi: 10.1038/srep41105.

Supplemental Content

Support Center